Sign In
Buy CYTK
$80.01
+0.84 (+1.06%)
At Close: Jun 23, 2026
Needham Reiterates a Buy Rating on Cytokinetics (CYTK)
02:59pm, Tuesday, 14'th Apr 2020
In a report released today, Chad Messer from Needham reiterated a Buy rating on Cytokinetics (CYTK), with a price target of $24.00. The company's shares
Needham Reiterates a Buy Rating on Cytokinetics (CYTK)
02:59pm, Tuesday, 14'th Apr 2020
In a report released today,
Chad Messer
from Needham reiterated a
Buy
rating on Cytokinetics (
CYTK
–
Research Report
), with a price target of
$24.00
. The company’s shares closed last Tuesday at
Cytokinetics suspends enrollment in clinical studies amid COVID-19; shares down 7% premarket
12:17pm, Tuesday, 14'th Apr 2020
Cytokinetics (NASDAQ:CYTK) provides clinical updates in response to COVID-19 pandemic. The company and Amgen have agreed to temporarily suspend enrollment in METEORIC-HF, Phase 1 study of AMG 594 an
Cytokinetics says cash, cash equivalents represent over two years of runway CYTK
11:47am, Tuesday, 14'th Apr 2020
Cytokinetics says cash, cash equivalents represent over two years of runway CYTK
Cytokinetics, Amgen suspend enrollment in Phase 1 study of AMG 594 CYTK;AMGN
11:47am, Tuesday, 14'th Apr 2020
Cytokinetics, Amgen suspend enrollment in Phase 1 study of AMG 594 CYTK AMGN
